PresentationWe're back now with Alumis for a fireside chat. We have CEO, Martin Babler; and CFO, John Schroer for a fireside. Maybe I'll start off by sending it back to Martin for a quick company overview, and then we'll jump into the Q&A.Martin BablerPresident, CEO & Chairman Thank you, Alex. So we're Alumis. We are about a 4-year-old company. We're a precision immunology company with a focus on our lead asset being a TYK2 inhibitor. We have three clinical molecules and a research pipeline behind that. And ...